Rapid response to spesolimab in a patient with severe refractory pyoderma gangrenosum-Reference-Cited by-同舟云学术

Rapid response to spesolimab in a patient with severe refractory pyoderma gangrenosum

Published:2023-09-14 Issue:1 Volume:49 Page:82-84
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Ma Li¹^ORCID,Chen Xiaohong¹,Guo Qing¹,Qiao Zhuhui¹,Wang Nansong²,Pai Pearl³,Liu Xiaoming¹

Affiliation:

1. Departments of Dermatology

2. Pharmacy

3. Internal Medicine, The University of Hongkong-Shenzhen Hospital , Shenzhen , China

Abstract

We report on a patient with severe ulcerative pyoderma gangrenosum that was recalcitrant to systemic corticosteroid, tumour necrosis factor antagonist and ciclosporin treatment and finally controlled when spesolimab was added to the treatment regimen.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llad317/52174608/llad317.pdf

Reference4 articles.

1. Pyoderma gangrenosum;Maverakis;Nat Rev Dis Primers,2020

2. Trial of spesolimab for generalized pustular psoriasis;Bachelez;N Engl J Med,2021

3. Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials;Partridge;Br J Dermatol,2018

4. Are neutrophilic dermatoses autoinflammatory disorders?;Satoh;Br J Dermatol,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between pyoderma gangrenosum and autoimmune connective tissue disorders: A systematic review;International Journal of Dermatology;2024-02-25

2. Multiple drugs;Reactions Weekly;2024-02-24

3. The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives;International Journal of Molecular Sciences;2024-02-19

4. Journal Club: Update on pyoderma gangrenosum;European Journal of Dermatology;2023-10